Sale!

BCS1L Gene Mitochondrial Complex III Deficiency Genetic Test

Original price was: $700.Current price is: $500.

-29%

The BCS1L Gene Mitochondrial Complex III Deficiency NGS Genetic DNA Test is a cutting-edge genetic analysis that identifies mutations in the BCS1L gene, which plays a crucial role in mitochondrial energy production. This comprehensive test utilizes next-generation sequencing technology to detect genetic variations associated with mitochondrial complex III deficiency, a rare neurological disorder affecting cellular energy metabolism. Patients experiencing symptoms such as developmental delays, muscle weakness, neurological deterioration, or metabolic acidosis should consider this test. The test provides definitive diagnosis, enables personalized treatment strategies, and offers genetic counseling guidance for family planning. Available for only $500 USD, this advanced genetic screening delivers critical insights into mitochondrial function and helps guide appropriate medical interventions for improved patient outcomes.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

BCS1L Gene Mitochondrial Complex III Deficiency NGS Genetic DNA Test

Comprehensive Genetic Analysis for Mitochondrial Disorders

The BCS1L Gene Mitochondrial Complex III Deficiency NGS Genetic DNA Test represents a breakthrough in neurological genetic diagnostics, offering precise detection of mutations in the BCS1L gene that are responsible for mitochondrial complex III deficiency. This sophisticated genetic analysis provides crucial insights into cellular energy production disorders that can significantly impact neurological function and overall health.

What This Advanced Genetic Test Measures

This comprehensive NGS-based genetic test specifically targets the BCS1L gene, which encodes an essential protein involved in the assembly of mitochondrial complex III – a critical component of the electron transport chain. The test detects:

  • Point mutations and single nucleotide variants in the BCS1L gene
  • Insertions and deletions affecting gene function
  • Pathogenic variants associated with mitochondrial complex III deficiency
  • Genetic markers linked to impaired cellular energy production
  • Inheritance patterns for genetic counseling purposes

Who Should Consider This Genetic Test

This specialized genetic testing is recommended for individuals presenting with symptoms suggestive of mitochondrial disorders, including:

  • Infants and children with developmental delays or regression
  • Patients experiencing progressive muscle weakness or hypotonia
  • Individuals with unexplained neurological deterioration
  • Patients with metabolic acidosis or lactic acidosis
  • Those with family history of mitochondrial disorders
  • Children with failure to thrive or growth retardation
  • Patients with seizures or movement disorders of unknown origin
  • Individuals with vision or hearing loss associated with neurological symptoms

Significant Benefits of Genetic Testing

Undergoing the BCS1L Gene Mitochondrial Complex III Deficiency test provides numerous advantages for patients and healthcare providers:

  • Accurate Diagnosis: Provides definitive identification of genetic causes for neurological symptoms
  • Personalized Treatment: Enables targeted therapeutic interventions based on genetic findings
  • Family Planning Guidance: Offers crucial information for genetic counseling and reproductive decisions
  • Early Intervention: Facilitates timely medical management to prevent disease progression
  • Prognostic Information: Helps predict disease course and potential complications
  • Research Contribution: Advances understanding of mitochondrial disorders

Understanding Your Test Results

Your genetic test results will be carefully interpreted by our team of certified genetic counselors and neurologists:

  • Positive Result: Indicates the presence of pathogenic BCS1L gene mutations, confirming mitochondrial complex III deficiency diagnosis
  • Negative Result: Suggests absence of detectable mutations in the BCS1L gene, though other genetic causes may need investigation
  • Variant of Uncertain Significance: Identifies genetic changes with unknown clinical impact, requiring further evaluation
  • Carrier Status: Determines if you carry one copy of a mutated gene, important for family planning decisions

All results include comprehensive interpretation and recommendations for next steps in medical management.

Test Pricing and Details

Test Feature Details
Test Name BCS1L Gene Mitochondrial Complex III Deficiency NGS Genetic DNA Test
Discount Price $500 USD
Regular Price $700 USD
Turnaround Time 3 to 4 Weeks
Sample Type Blood, Extracted DNA, or One Drop Blood on FTA Card
Testing Method Next-Generation Sequencing (NGS) Technology

Pre-Test Preparation Requirements

To ensure optimal testing outcomes, please prepare the following:

  • Complete clinical history documentation of the patient
  • Schedule a genetic counseling session with our specialists
  • Provide detailed pedigree chart of family members affected by mitochondrial disorders
  • Bring any previous medical records or test results

Nationwide Testing Availability

We proudly offer comprehensive genetic testing services across the United States with convenient locations in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art laboratories ensure consistent, high-quality results regardless of your location.

Take Action for Better Health Outcomes

Don’t let uncertainty about neurological symptoms delay your path to accurate diagnosis and effective treatment. Our specialized genetic testing provides the clarity needed for informed medical decisions and personalized care planning.

Ready to schedule your genetic test? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Take the first step toward understanding your genetic health and accessing targeted treatment options.